User login
Key clinical point: Study finds direct evidence of transient neurotoxicity immediately after immunoablative autologous hematopoietic stem cell transplantation (IAHSCT) for aggressive multiple sclerosis (MS).
Major finding: Three months post-IAHSCT, levels of serum markers of both neuroaxonal and glial cell injury (serum Neurofilament Light Chain [sNfL] and serum Glial Fibrillary Acidic Protein [sGFAP]) increased from baseline by 32.1% (P = .029) and 74.8% (P = .0004), respectively. sNfL increases correlated with the dose of busulfan administered during transplant conditioning (P = .034), Expanded Disability Status Scale score (P = .041), as well as brain volume loss (P = .044), attributed to gray matter loss (P = .0023).
Study details: sNfL and sGFAP levels were evaluated pre- and post-IAHSCT at 3, 6, 9, and 12 months in 22 patients with MS and 28 noninflammatory control participants.
Disclosures: The study was funded by the MS Society of Canada. The authors declared no conflict of interest.
Citation: Thebault S et al. Ann Clin Transl Neurol. 2020 Apr 18. doi: 10.1002/acn3.51045.
Key clinical point: Study finds direct evidence of transient neurotoxicity immediately after immunoablative autologous hematopoietic stem cell transplantation (IAHSCT) for aggressive multiple sclerosis (MS).
Major finding: Three months post-IAHSCT, levels of serum markers of both neuroaxonal and glial cell injury (serum Neurofilament Light Chain [sNfL] and serum Glial Fibrillary Acidic Protein [sGFAP]) increased from baseline by 32.1% (P = .029) and 74.8% (P = .0004), respectively. sNfL increases correlated with the dose of busulfan administered during transplant conditioning (P = .034), Expanded Disability Status Scale score (P = .041), as well as brain volume loss (P = .044), attributed to gray matter loss (P = .0023).
Study details: sNfL and sGFAP levels were evaluated pre- and post-IAHSCT at 3, 6, 9, and 12 months in 22 patients with MS and 28 noninflammatory control participants.
Disclosures: The study was funded by the MS Society of Canada. The authors declared no conflict of interest.
Citation: Thebault S et al. Ann Clin Transl Neurol. 2020 Apr 18. doi: 10.1002/acn3.51045.
Key clinical point: Study finds direct evidence of transient neurotoxicity immediately after immunoablative autologous hematopoietic stem cell transplantation (IAHSCT) for aggressive multiple sclerosis (MS).
Major finding: Three months post-IAHSCT, levels of serum markers of both neuroaxonal and glial cell injury (serum Neurofilament Light Chain [sNfL] and serum Glial Fibrillary Acidic Protein [sGFAP]) increased from baseline by 32.1% (P = .029) and 74.8% (P = .0004), respectively. sNfL increases correlated with the dose of busulfan administered during transplant conditioning (P = .034), Expanded Disability Status Scale score (P = .041), as well as brain volume loss (P = .044), attributed to gray matter loss (P = .0023).
Study details: sNfL and sGFAP levels were evaluated pre- and post-IAHSCT at 3, 6, 9, and 12 months in 22 patients with MS and 28 noninflammatory control participants.
Disclosures: The study was funded by the MS Society of Canada. The authors declared no conflict of interest.
Citation: Thebault S et al. Ann Clin Transl Neurol. 2020 Apr 18. doi: 10.1002/acn3.51045.